← All trials
NCT05352828
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2022
- Primary completion
- Dec 15, 2025
- Completion date
- Dec 15, 2037
- First posted
- Apr 29, 2022
- Last posted
- Sep 28, 2022
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tessa TherapeuticsLead sponsor
- Baylor UniversityOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- Baylor UniversityOfficial
- Bristol-Myers SquibbCollaborator
- University of Texas at HoustonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.